98%
921
2 minutes
20
Oral tongue squamous cell carcinoma (OTSCC) was one of the most hypoxic tumors with unfavorable outcomes. Hypoxia-inducible factor-1 (HIF-1) signaling was associated with cancer proliferation, lymph node metastasis, angiogenesis and poor prognosis of OTSCC. Dihydroorotate dehydrogenase (DHODH) catalyzed the rate-limiting step in the de novo pyrimidine biosynthesis. The aim of the study was to explore the biological function of DHODH and investigate whether DHODH regulated HIF-1 signaling in OTSCC. Proliferation, migration and anoikis resistance were used to determine the function of DHODH. Western blot and luciferase activity assays were used to determine the regulatory role of DHODH on HIF-1. We found that increased DHODH expression was associated with advanced tumor stage and poorly differentiated tumor in head and neck cancer patients in The Cancer Genome Atlas (TCGA). DHODH enhanced the proliferation and aggressiveness of OTSCC. Moreover, DHODH prompted tumor growth and metastasis . DHODH promoted transcription, protein stability, and transactivation activity of HIF1A. DHODH-induced HIF1A upregulation in OTSCC can be reversed by reactive oxygen species (ROS) scavenger, indicating that DHODH enhanced HIF1A expression via ROS production. DHODH inhibitor suppressed DHODH-mediated ROS generation and HIF1A upregulation. Targeting DHODH using clinically available inhibitor, atovaquone, might provide a new strategy to treat OTSCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822278 | PMC |
Front Med (Lausanne)
August 2025
First Clinical Medical School, Gansu University of Chinese Medicine, Lanzhou, Gansu Province, China.
Background: Carbon-ion radiotherapy (CIRT) is an advanced form of high linear energy transfer (LET) radiotherapy that has demonstrated superior biological effectiveness compared to conventional photon therapy in the treatment of various malignancies; however, its role in gastric cancer remains unclear. Dihydroorotate dehydrogenase (DHODH), a key enzyme implicated in cancer progression, has been linked to tumor radiosensitivity. This study aims to investigate whether CIRT inhibits gastric cancer progression via the regulation of DHODH.
View Article and Find Full Text PDFBiochemistry
September 2025
Loyola University Chicago, Department of Chemistry and Biochemistry, 1068 W Sheridan Rd, Chicago, Illinois 60660, United States.
Dihydroorotate dehydrogenase 1B (DHOD1B) is one of several flavoproteins that utilize active half-sites. These enzymes have two flavin cofactors (FAD and FMN) that each interact with a specific reductant/oxidant substrate/product. Electrons gained at one-half-site must be transmitted to the other half-site and iron-sulfur centers between the flavin cofactors serve in this role.
View Article and Find Full Text PDFBiochem Pharmacol
August 2025
Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao 266011, China. Electronic address:
Cervical carcinoma remains a major public health challenge due to its elevated incidence and mortality rates. Dihydroorotate dehydrogenase (DHODH) is a crucial enzyme in de novo pyrimidine biosynthesis and ferroptosis defense with a targetable susceptibility in cancer. However, effective inhibitors of DHODH and their potential application in cervical cancer therapy have not yet been explored.
View Article and Find Full Text PDFBr J Pharmacol
August 2025
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Background: Hepatocellular carcinoma (HCC), a globally prevalent malignancy with high mortality rates, presents an unmet need for innovative effective therapies.
Purpose: This study aimed to explore the antitumour potential of compound XD, a novel oridonin derivative, on HCC and its underlying mechanism.
Experimental Approach: The antitumour effects of compound XD were investigated in several HCC cells lines and mice models.
Bioorg Med Chem
August 2025
School of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin 300354, China; Hangzhou Institute of Medicine, Chinese Academy of Science, Hangzhou 310018, China; School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China. Electronic address: xfang@ic
Mitochondrial proteostasis is essential for tumorigenesis, and mitochondrial inner membrane proteins have emerged as meaningful targets due to their crucial functions in regulating apoptosis, maintaining oxidative phosphorylation, and influencing tumor initiation and progression. Targeted protein degradation (TPD) has garnered significant attention as a promising therapeutic approach. However, conventional TPD platforms relying on the ubiquitin-proteasome system or lysosomal pathways encounter inherent obstacles in targeting proteins sequestered within the mitochondrial compartment and cannot degrade mitochondrial inner membrane proteins.
View Article and Find Full Text PDF